Clinical Trials on Recurrent Squamous Cell Lung Carcinoma in Korea, Democratic People's Republic of

Total 1003 results

Yonsei University

Recruiting

Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers

Clear Renal Cell Cancer (< 7cm Size)

Korea, Republic of
Yonsei University

Completed

Effect of Ketorolac and Remote Ischemic Preconditioning on Renal Ischemia-reperfusion Injury in Patients Undergoing Partial Nephrectomy

Renal Cell Carcinoma

Korea, Republic of
Asan Medical Center

Unknown

Gemcitabine-Carboplatin Versus Gemcitabine-Oxaliplatin in Cisplatin-unfit Urothelial Carcinoma (COACH)

Advanced Urothelial Carcinoma

Korea, Republic of
Novartis Pharmaceuticals

Terminated

Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy

Head and Neck Squamous Cell Carcinoma

Germany, United Kingdom, United States, Spain, Italy, Canada, Poland, Russian Federation, Switzerland, Thailand, Korea, Republic of, Hungary, Ireland, Australia, Taiwan, France, India, Japan
Korea University Guro Hospital
Chong Kun Dang Pharmaceutical Corp.

Active, not recruiting

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

EGFR Positive Non-small Cell Lung Cancer

Korea, Republic of
Pfizer

Completed

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

Squamous Cell Carcinoma of the Head and Neck (SCCHN)

United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
Seoul National University Hospital

Completed

Magnetic Resonance Elastography (MRE) as a Predictor of HCC Recurrence After Radiofrequency Ablation (RFA) (MRE)

Hepatocellular Carcinoma | Hepatic Fibrosis

Korea, Republic of
Novartis Pharmaceuticals

Terminated

Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy (GEOMETRY-E)

Carcinoma, Non-Small-Cell Lung

Japan, Korea, Republic of, Singapore
AstraZeneca

Terminated

A Phase I Study of AZD1480 in Patients With Advanced Solid Malignancies and Advanced Hepatocellular Carcinoma in the Escalation Phase,Non-Small Cell Lung Cancer(NSCLC) and Non-smokers With Lung Metastasis and Gastric Cancer and Solid Tumour in the Expansion Phase.

Gastric Cancer | Advanced Solid Malignancies | Solid Tumour | Child-Pugh A to B7 Advanced Hepatocellular Carcinoma | EGFR and/or ROS Mutant NSCLC | Lung Metastasis Carcinoma

Korea, Republic of
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

Spain, United States, United Kingdom, France, Thailand, Malaysia, Mexico, Romania, Poland, Japan, Moldova, Republic of
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer

Squamous Cell Carcinoma of the Head and Neck

United States, Italy, Japan, Spain, Taiwan, Korea, Republic of, France, Poland, Russian Federation, Turkey
AstraZeneca
Parexel

Terminated

TAURAS - T790 AURA ScreenFailure SOC Registry Study (TAURAS)

Non Small Cell Lung Cancer

United States, Korea, Republic of
Seoul National University Hospital

Completed

Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus

Carcinoma, Renal Cell | Thrombus

Korea, Republic of
Sanofi
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)

Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Oesophageal Adenocarcinoma | Oesophageal Squamous Cell Carcinoma

Korea, Republic of, Belgium, Italy, United States, Chile, China, France, Netherlands, Spain
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck (SKYSCRAPER-09)

Squamous Cell Carcinoma of Head and Neck

United States, Korea, Republic of, United Kingdom, Czechia, New Zealand, France, Spain, Greece, Thailand, Taiwan, Hungary, Italy, Poland
Ono Pharmaceutical Co. Ltd

Completed

ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer

Advanced Non-small Cell Lung Cancer

Korea, Republic of
MitoImmune Therapeutics

Recruiting

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients (MIT-001)

Head and Neck Squamous Cell Carcinoma | Oral Mucositis

Korea, Republic of, United States
Samsung Medical Center

Recruiting

Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma (SABLOR)

Kidney Neoplasm

Korea, Republic of
Pfizer

Completed

A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Korea, Republic of, United States
SN BioScience

Not yet recruiting

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Small-cell Lung Cancer | Pancreas Cancer

Korea, Republic of
Asan Medical Center

Completed

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Capecitabine | Temozolomide

Korea, Republic of
Incyte Biosciences International Sàrl

Recruiting

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States, Taiwan, Italy, Korea, Republic of, Spain, France, Portugal, Germany, Poland, Canada, Georgia, Greece, Netherlands, Belgium
Johnson & Johnson Enterprise Innovation Inc.

Recruiting

A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-small-Cell Lung

Korea, Republic of, United States, Spain, Germany
AstraZeneca

Recruiting

Korea Osimertinib Real World Evidence Study to Assess Safety and Efficacy - PLUS (KOREA-PLUS)

Carcinoma, Non-Small-Cell Lung

Korea, Republic of
Incyte Corporation
Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

Head and Neck Cancer

Canada, Spain, Korea, Republic of, United States, Austria, Japan, United Kingdom, Taiwan, Italy, Hungary, Australia, Turkey, Poland, Portugal
AstraZeneca
Innate Pharma

Active, not recruiting

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer (INTERLINK-1)

Squamous Cell Carcinoma of the Head and Neck

United States, France, Italy, Spain, Belgium, Canada, Taiwan, Switzerland, Korea, Republic of, Japan, Poland, Russian Federation, United Kingdom, Austria, Brazil, Germany, Netherlands, Portugal, Australia, Philippines, Bulgaria, G... and more
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Neoplasm

China, Taiwan, Korea, Republic of
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, United Kingdom, Spain
Yonsei University

Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA

Prostate Cancer | Bladder Cancer | Renal Cell Cancer | Ureter Cancer

Korea, Republic of
Medicenna Therapeutics, Inc.
Merck Sharp & Dohme LLC

Recruiting

A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)

Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions

United States, Australia, Korea, Republic of, Canada
Samsung Medical Center
National Evidence-Based Healthcare Collaborating Agency

Recruiting

The Prospective Non-randomized Case-control Study From Real-world Lung Cancer Patients (OPTIMUS)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of
Yonsei University

Recruiting

Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome

Prostate Cancer | Bladder Cancer | Renal Cell Cancer | Ureter Cancer | Urological Malignancies

Korea, Republic of
Hoffmann-La Roche

Active, not recruiting

A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus

Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Korea, Republic of, Argentina, Denmark, France, Spain, Brazil, United Kingdom, Turkey, Czechia, Thailand, Russian Federation, Italy, Poland, Taiwan, Singapore, Ukraine, Kenya, Hungary
Genexine, Inc.

No longer available

Individual Patient Compassionate Use of GX-I7

Melanoma | Glioblastoma | High Grade Glioma | Recurrent Glioblastoma | Advanced Cancer

Korea, Republic of
BeiGene

Recruiting

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

China, Italy, Taiwan, Australia, Spain, Korea, Republic of, France, United Kingdom, Thailand, Canada, United States, Georgia, Singapore, Turkey
Seoul National University Hospital

Unknown

Role of Perfusion CT in Pancreatic Cancer

Neuroendocrine Carcinoma of Pancreas | Adenocarcinoma, Pancreas

Korea, Republic of
Hoffmann-La Roche

Terminated

A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).

Small Cell Lung Cancer

Korea, Republic of, United States, Denmark, Spain
Korean Association of Endocrine Surgeons

Unknown

Diagnostic Utility of [18F]-FDG-PET/CT and [124I]-PET/CT for Detection of Recurrence in Differentiated Thyroid Carcinoma

Recurrence | Thyroid Cancer

Korea, Republic of
Pusan National University Yangsan Hospital

Recruiting

Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma

Urothelial Carcinoma | Neoadjuvant Chemotherapy | Muscle Invasive Bladder Cancer

Korea, Republic of
Seoul National University Hospital

Withdrawn

The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma

Hepatocellular Carcinoma | Lung Metastasis

Korea, Republic of
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)

Squamous Cell Carcinoma of the Head and Neck

Brazil, Italy, United Kingdom, United States, Hong Kong, France, Netherlands, Germany, Argentina, Canada, Japan, Korea, Republic of, Spain, Switzerland, Taiwan
Korean Association for the Study of Targeted Therapy
Chonnam National University Hospital; Kyungpook National University Hospital; Konkuk University Medical Center and other collaborators

Completed

Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)

HER2 Gene Mutation | Adenocarcinoma Lung Stage IV

Korea, Republic of
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

Australia, China, Korea, Republic of, Taiwan
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Samsung Medical Center

Recruiting

Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma

Lung Adenocarcinoma

Korea, Republic of
Samsung Medical Center
Korean Foundation for Cancer Research

Unknown

Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy

Lung Adenocarcinoma

Korea, Republic of
GlaxoSmithKline
Merck Sharp & Dohme LLC

Terminated

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (INDUCE-4)

Neoplasms, Head and Neck

United States, Argentina, Italy, Spain, Belgium, Denmark, Poland, Canada, Germany, Korea, Republic of, Ireland, Japan, United Kingdom, Romania, Hungary, Australia, France, Brazil, Sweden, Russian Federation
AstraZeneca

Active, not recruiting

Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)

Small-Cell Lung Cancer

Poland, Korea, Republic of, United States, Spain
Hoffmann-La Roche

Completed

A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation

Non-Squamous Non-Small Cell Lung Cancer

Spain, Taiwan, Japan, United States, France, Germany, Korea, Republic of, Malaysia
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Stage IV or Recurrent Non-Small Cell Lung Cancer

United States, Finland, Argentina, France, Italy, Brazil, Greece, Japan, Mexico, Romania, Spain, Sweden, United Kingdom, Australia, Austria, Belgium, Canada, Czechia, Germany, Hungary, Korea, Republic of, Netherlands, Poland, Switzerland and more

Clinical Trials on Recurrent Squamous Cell Lung Carcinoma in Korea, Democratic People's Republic of

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malawi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations